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Abstract: Argatroban is a synthetic direct thrombin inhibitor with a relative short elimina-
tion half-life of 45 minutes and elimination which is predominantly performed via hepatic 
metabolism. Argatroban anticoagulation has been systematically studied in patients exhibiting 
the heparin-induced thrombocytopenia (HIT)/thrombosis syndrome and demonstrated to be a 
safe and effective therapy in this indication. Moreover, in smaller studies argatroban has also 
been assessed in special clinical settings in non-HIT patients. The current review presents the 
pharmacology of argatroban, data regarding monitoring of the agent, and an overview of the 
results of the major clinical trials assessing argatroban anticoagulation in HIT patients. Addi-
tionally, data from clinical trials with argatroban use outside HIT, in more special indications 
such as in percutaneous coronary intervention, stroke, renal replacement therapy, and intensive 
care medicine, are reviewed.
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Introduction
Heparins, particularly unfractionated heparins (UFH), have been the standard anticoag-
ulants in nearly every ﬁ  eld of anticoagulation therapy for decades. However, increasing 
recognition of the limitations of efﬁ  cacy and safety of UFH therapy, particularly the 
hazard of heparin-induced thrombocytopenia (HIT), a severe disease in which heparin 
reverses its effect and may lead to thromboses, has promoted the development of new 
anticoagulants. The direct thrombin inhibitors (DTI), such as argatroban, bivalirudin, 
and lepirudin, are a class of potent anticoagulants that are playing an emerging role 
in modern anticoagulation therapy and are effective in the treatment of HIT-induced 
thromboembolism and as alternative anticoagulants for thrombosis prophylaxis in 
patients diagnosed for HIT. Furthermore, in special indications such as percutaneous 
coronary intervention (PCI), DTIs have demonstrated improved clinical results when 
compared with therapy with UFH (DTI Group. Argatroban, a small synthetic DTI, is 
the only alternative anticoagulant that in US jurisdiction is approved for both treatment 
of HIT-induced thromboembolism and prophylaxis of HIT. The current review presents 
the pharmacology of argatroban, an overview of the results of the major clinical trials 
assessing argatroban anticoagulation in HIT patients, and data from clinical trials with 
argatroban use outside HIT in more special indications such as in PCI, stroke, renal 
replacement therapy, and intensive care medicine.
Pharmacology of argatroban
Argatroban is a synthetic monovalent direct thrombin inhibitor, the molecular 
structure of which contains an arginine residue. Argatroban is highly selective for 
thrombin and has little or no effect on related serine proteases (trypsin, factor Xa, 
plasmin, and kallikrein). Argatroban is effective against free, ﬁ  brin-bound and clot-
bound thrombin with comparable half-maximal inhibitory concentrations (IC50), and Biologics: Targets & Therapy 2007:1(2) 106
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argatroban is also effective in inhibiting platelet aggregation 
and thromboxane generation in the presence of both free and 
clot-bound thrombin. These pharmacologic properties are 
distinctly different from those of hirudin and heparin, for 
which markedly higher concentrations are required to inhibit 
clot bound thrombin in contrast to free thrombin (Berry et al 
1994; Di Nisio et al 2005).
Argatroban is hepatically metabolized by hydroxylation 
and aromatization (mainly by CYP 3A4) to 4 main metabo-
lites which do not possess relevant pharmacologic activity. 
Within a clinically relevant dose range (from 1–3 μg/kg/min 
in prevention or treatment of thrombotic events in HIT to up 
to 25 μg/kg/min in PCI in HIT patients), argatroban exhibits 
linear pharmacokinetic behavior, and steady state levels 
are attained within 1 hour after the start of an infusion. The 
elimination half-life of argatroban in healthy subjects is about 
45 minutes, with a corresponding decline in its anticoagulant 
effects which reach their pretreatment level within 2–4 hours 
after cessation of an infusion. The pharmacokinetic proﬁ  le 
can best be described by reference to a 2-compartment model 
with ﬁ  rst-order elimination; effect response and plasma 
argatroban concentrations were well correlated (Swan and 
Hursting 2000). Argatroban lacks major drug–drug interac-
tions with CYP3A4/5 inhibitors such as erythromycin (Tran 
et al 1999) or with acetaminophen, warfarin, and digoxin 
(Brown and Hursting 2002; Inglis et al 2002). There have 
been several studies which characterize the pharmacokinetic 
and pharmacodynamic properties of argatroban in vulnerable 
patient groups, ie, elderly patients and patients with renal 
and/or hepatic dysfunction. The only effect of age or gender 
was an approximately 20% lower clearance in elderly men 
versus elderly women, which does not translate into clinically 
or statistically signiﬁ  cant differences in pharmacodynamic 
response (Swan and Hursting 2000). In patients with various 
degrees of renal dysfunction down to a creatinine clearance 
of 30 mL/min, no signiﬁ  cant differences in the pharmaco-
dynamic or pharmacokinetic proﬁ  les were detected (Swan 
and Hursting 2000). However, in patients with hepatic 
impairment, area under the concentration versus time curve 
(AUC), maximum concentration, and half-life of argatroban 
were increased approximately 2- to 3-fold, and clearance was 
one-fourth that of healthy volunteers. The increase in plasma 
concentrations in these patients coincided with increased 
pharmacodynamic effects (Swan and Hursting 2000). 
Dosing precautions are therefore recommended in patients 
with hepatic dysfunction, with reduced doses required 
particularly in patients with serum total bilirubin levels 
25.5 μmol/L (1.5 mg/dL) or combined hepatic/renal 
dysfunction (Levine et al 2006). It should be noted that, currently, 
no antidote to direct thrombin inhibitors is available.
Monitoring of argatroban 
anticogulation
Argatroban effects can be described using a variety of 
coagulation parameters, with a close dose/concentration 
vs effect relationship (Harder et al 2004). In most clinical 
studies, argatroban effects have been monitored by ACT 
(predominantly in high-dose therapy, eg, PCI setting) or 
aPTT (activated partial thromboplastin time) (in prevention/
treatment of thrombosis in HIT). An infusion of 2 μg/kg/min 
argatroban is expected to increase aPTT 1.5-fold, whereas 
an infusion of 10 μg/kg/min can prolong a PTT up to 3-fold. 
In the PCI setting, the ACT is prolonged to 275–450 sec 
under 15–25 μg/kg/min argatroban (Yeh and Jang 2006). 
Although aPTT is an accepted coagulation parameter suit-
able to monitor argatroban in most clinical applications, 
its value has been challenged by the observation that the 
aPTT response to argatroban varies with the aPTT reagent, 
and approximately 1.5-fold differences in the prolongation 
of aPTT under the same concentration of argatroban have 
been observed between one reagent and another (Francis and 
Hursting 2005). In contrast, the ecarin clotting time (ECT) 
is a more speciﬁ  c monitoring parameter for direct thrombin 
inhibitors (Harder et al 2004), and a prolongation to 1.5- to 
2-fold is attained by infusion of 2 μg/kg/min. However, assays 
vary considerably and unfortunately no point of care (POC) 
test for the ECT is commercially available.
Although not desired as a monitoring parameter, 
prothrombin time (PT) is also prolonged by argatroban, 
depending on the ISI of the PT reagent (Harder et al 2004). 
Argatroban furthermore decreases the endogenous thrombin 
potential in a dose/concentration dependent manner (Harder 
et al 2004).
Transition from argatroban 
anticoagulation to oral 
anticoagulants
After intravenous anticoagulation, often transition to a pro-
longed period of oral anticoagulation with coumarin deri-
vates is necessary. The effectiveness and safety of therapy 
with coumarin derivates are usually monitored using the PT 
expressed as the international normalized ratio (INR). Most 
publications related to warfarin suggest that an INR 4.0 
is associated with an increased risk for bleeding complica-
tions (Bartholomew and Hursting 2005). All direct thrombin Biologics: Targets & Therapy 2007:1(2) 107
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inhibitors have an inﬂ  uence on the INR values, but this is 
particularly true of argatroban, presumably due to the high 
molar plasma concentration necessary to achieve effective 
thrombin inhibition (Warkentin et al 2005). This complicates 
the transition to oral anticoagulation when argatroban is 
used. Although no standard protocol exists, the most com-
mon procedure, which is included in the package advice, 
is to overlap with warfarin for a minimum of 4–5 days, 
aiming at an INR of 4 (Harder et al 2004). Once this level 
is attained, argatroban therapy should be discontinued and 
testing of the INR repeated after approximately 6 hours to 
ensure that the therapeutic range is maintained (Bartholomew 
2005). However, a retrospective analysis of the data of 111 
patients from the ARG-911 and ARG-915 investigations 
who received argatroban/warfarin co-therapy and transition 
demonstrated that 5 (4.5%) patients experienced new throm-
boembolic complications during overlap at an INR value of 
4 but that only one patient (0.9%) experienced bleeding 
complications (Bartholomew and Hursting 2005). These data 
suggest that, particularly in patients with thrombotic HIT, 
during warfarin/argatroban co-therapy at an INR value of 
4, the risk for thrombosis exceeds the risk for hemorrhage, 
so that in doubt higher INR values may be advisable in this 
special patient population. This suggestion is supported 
by other data from 165 HIT patients which demonstrated 
that INR values of 5 during argatroban monotherapy and 
argatroban/warfarin combination therapy frequently occur 
without increasing the risk for major bleeding complications 
(Hursting et al 2005).
As discussed in the following sections, special patient 
populations, such as intensive care unit (ICU) patients and 
patients who have undergone cardiovascular surgery, reveal 
increased sensitivity to argatroban anticoagulation, thus 
requiring signiﬁ  cant dose reductions. As particularly the 
molar concentration of argatroban appears to be responsible 
for interference with the INR, further studies should assess 
the extent to which the signiﬁ  cant dose reduction in these 
patient populations also has implications for the effect of 
argatroban on the INR and the practice of transition to cou-
marin therapy.
Argatroban anticoagulation 
in patients with HIT
Agatroban anticoagulation 
in the treatment of acute HIT
In patients diagnosed for HIT, antibodies directed against the 
complex of heparin and platelet factor 4 (PF4) are generated. 
The antigen/antibody complexes bind to the Fc receptor of 
platelets and induce platelet activation. Activated platelets on 
the one hand release PF4, thus causing increased formation 
of antigen/antibody complexes, and on the other hand cause 
the massive activation of thrombin, which is the most potent 
intrinsic activator of platelets. This massive generation of 
thrombin establishes a severe hypercoagulant condition that 
may ﬁ  nally lead to consumption of platelets and thrombin in 
thromboembolic events such as peripheral and mesenteric 
thrombosis and embolism, myocardial infarction, and stroke 
(Warkentin 2004a, b). The condition of HIT/HIT thrombosis 
syndrome (HIT(TS)) requires the immediate institution of 
alternative anticoagulation to prevent or treat these throm-
boembolic complications. As the “thrombin burst” plays a 
central role in this cascade of events, potent inhibition of 
thrombin action is the central therapeutic act in the treatment 
of the disease. As DTIs are among the most potent inhibitors 
of thrombin, this class of agents, particularly lepirudin and 
argatroban, has been intensively studied in this regard.
The safety and efﬁ  cacy of argatroban anticoagulation for 
treatment of acute HIT(TS) has been assessed in two large 
prospective trials which were similar in their study design: 
the ARG-915 study and the ARG-911 study (Lewis et al 
2001, 2003). Due to the lack of an approved competitor, the 
outcome of patients diagnosed for HIT and or thrombotic 
HIT and treated with argatroban was compared with that 
of an historical control group in which therapy followed 
the local departmental standards. Argatroban therapy was 
initiated with a continuous infusion of 2 μg/kg/min which 
could be adjusted to a maximum of 10 μg/kg/min in order 
to achieve a prolongation of the aPTT to a target value of 
1.5–3 times of baseline but a maximum of 100 seconds. The 
prospectively deﬁ  ned primary endpoints of efﬁ  cacy were the 
composite of death from all causes, all cause amputation and 
new thrombosis within 37 days. Among the safety endpoints 
the bleeding data were most important.
The efficacy and safety outcomes are presented in 
Tables 1 and 2. In both studies argatroban anticoagulation 
resulted in a signiﬁ  cant reduction of the composite endpoint in 
the HIT population and a marked but not signiﬁ  cant reduction 
of the composite endpoint in the HITTS population. Major 
bleeding complications were observed in 3%–6 % of argatro-
ban treated patients except for 11.1% in the HITTS population 
of the ARG-911 trial. These results were observed with a mean 
argatroban dose of 1.7 ± 1 μg/kg/min in the ARG 915 study 
and 1.9-2.0 ± 0.1 μg/kg/min in the ARG-911 study.
The direct thrombin inhibitor lepirudin, which is exclu-
sively eliminated via the kidneys and has a longer plasma Biologics: Targets & Therapy 2007:1(2) 108
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elimination half-life of 60–80 min, had been assessed for 
treatment of acute HIT(TS) (Greinacher et al 1999a, b). While 
clinical outcomes were comparable with the results obtained 
in the argatroban trials and demonstrated improved efﬁ  cacy 
compared with the historical control groups, major bleeding 
events were observed in 12.9%–13.4% of patients.
A limitation of the argartoban/HIT trials must be noted 
that, in contrast to the studies with lepirudin where the diag-
nosis of HIT had to be proven in a functional washed platelet 
aggregation assay, in the ARG-911 and ARG 915 trials the 
diagnosis of HIT was only based on the absolute platelet 
count, or course of the platelet count and not conﬁ  rmed in 
an antigen or functional HIT assay. Therefore patients may 
have been enrolled in this study who did not experience HIT 
but a decrease of the platelet count due to other comorbidi-
ties or medications.
Argatroban anticoagulation during 
percutaneous coronary intervention
Three prospective studies, the ARG-216, ARG-310, and 
ARG-311 studies, have been performed to evaluate the safety 
and efﬁ  cacy of argatroban anticoagulation during PCI [22]. 
Patients were followed during argatroban infusion and 24 
hours after its cessation (or until hospital discharge) for the 
occurrence of death, emergency coronary artery bypass graft 
surgery, repeat PCI, myocardial infarction, and bleeding. 
Argatroban was given with an initial bolus of 350 μg/kg 
(up to 3 additional boluses of 150 μg/kg were allowed) 
followed by a continuous infusion of 25 μg/kg/min (which 
could be adjusted to 15–40 μg/kg/min) in order to achieve 
a target activated clotting time (ACT) of 300–450 seconds 
during the intervention.
A total of 91 patients underwent 112 separate coronary 
interventions. The mean infusion dose of argatroban was 
23 μg/kg/min; 25 patients received a second bolus of arg-
atroban and 4 patients a third. Among all patients 92.3% 
remained free from all major acute complications and 97.7% 
achieved angiographic and clinical success. The overall inci-
dence of death, myocardial infarction, or revascularization 
at 24 hours was 6.3% with an overall major bleeding rate of 
0.9% (Lewis et al 2002).
Argatroban in intensive care 
and cardiosurgical HIT patients
In the large ARG-911 and ARG-915 studies intravenous 
argatroban anticoagulation was started with a dose of 2 μg/
kg/min and adjusted to achieve a target aPTT prolongation 
of 1.5–3 of baseline value with a maximum of 10 μg/kg/min 
and maximum aPTT value of 100 seconds (Lewis et al 2001, 
2003). Even taking into consideration the large variability 
of the dose effect of argatroban on different aPTT reagents 
(Francis and Hursting 2005), both studies showed that the 
Table 1 Efﬁ  cacy and safety outcomes in the ARG-911 trial
Outcome   HIT    p value  HITTS    p value
 Control  Argatroban    Control  Argatroban
  (n = 147)  (n = 160)    (n = 46)  (n = 144)
Composite end point  57 (38.8%)  41 (25.6%)  0.0014  26 (56.5%)  63 (43.8%)  0.131
Death  32 (21.8%)  27 (16.9%)  0.311  13 (28.3%)  26 (18.1%)  0.146
Amputation  3 (2%)  3 (1.9%)  1.000  4 (8.7%)  16 (11.1%)  0.787
New thrombosis  22 (15%)  11 (6.9%)  0.027  9 (19.6%)  21 (14.6%)  0.486
Major bleeding  12 (8.2%)  5 (3.1%)  0.078  1 (2.2%)  16 (11.1%)  0.077
Abbreviations: HIT, heparin-induced thrombocytopenia; HITTS, HIT/HIT thrombosis syndrome.
Table 2 Efﬁ  cacy and safety outcomes in the ARG-915 trial
Outcome   HIT    p value  HITTS    p value
 Control  Argatroban    Control  Argatroban
  (n = 139)  (n = 189)    (n = 46)  (n = 229)
Composite end point  54 (38.8%)  53 (28 %)  0.04  26 (56.5%)  95 (41.5%)  0.07
Death  29 (20.9%)  36 (19%)  0.78  13 (28.3%)  53 (23.1%)  0.45
Amputation  4 (2.9%)  8 (4.2%)  0.57  5 (10.9%)  34 (14.8%)  0.64
New thrombosis  32 (23%)  11 (5.8%)  <0.001  16 (34.8%)  30 (13.1%)  <0.001
Major bleeding  12 (8.6%)  10 (5.3%)  0.27  1 (2.2%)  14 (6.1%)  0.48
Abbreviations: HIT, heparin-induced thrombocytopenia; HITTS, HIT/HIT thrombosis syndrome.Biologics: Targets & Therapy 2007:1(2) 109
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anticoagulant effect was quickly achieved with a bolus and 
that minimal dose adjustments were necessary to maintain 
the aPTT within the target range. However, there are case 
reports of a dramatic overshoot of the aPTT with this stan-
dard dose when given to patients on the (ICU) or patients 
following cardiac surgery (Reichert et al 2003; Williamson 
et al 2004; Koster et al 2006; Beiderlinden et al 2007). In 
a recent investigation in critically ill patients with multiple 
organ dysfunction and suspected HIT, the dosing of argatro-
ban had to be reduced to 0.2 μg/kg/min to avoid excessive 
anticoagulation and bleeding (Beiderlinden et al 2007).
First data of the European ARG-E03 study of patients 
having undergone cardiovascular surgery conﬁ  rmed this 
observation (Koster et al 2006). In 18 of 20 patients after 
cardiovascular surgery the initial infusion dose was reduced 
to 1 μg/kg/min and in most patients the continuous infusion 
was further reduced to approximately 0.5 μg/kg/min during 
the further clinical course. This dose of 0.5 μg/kg/h was also 
conﬁ  rmed to be the most appropriate in ICU patients with 
renal failure and liver dysfunction. These data suggest that 
there are signiﬁ  cant differences in the susceptibility of special 
patient populations.
Argatroban has also been used for anticoagulation during 
cardiac surgery with and without cardiopulmonary bypass 
(CPB). However, to date no comprehensive dosing proto-
col for argatroban anticoagulation in these settings exists 
and both bleeding complications and thrombosis of CPB 
circuits have been observed (Monte et al 2007). Therefore, 
to date, the use of argatroban in this indication should be 
discouraged.
Argatroban anticoagulation 
in patients without HIT(TS)
Argatroban anticoagulation during 
percutaneous coronary intervention 
and myocardial infarction
An open label study enrolling 152 patients investigated arg-
atroban anticoagulation in conjunction with a platelet glyco-
protein IIb/IIIa (GP IIb/IIIa) antagonist during PCI (Jang et al 
2004). Argatroban was given with a bolus of 250 or 300 μg/kg 
followed by an infusion of 15 μg/kg/min together with the 
GP IIb/IIIa antagonists eptiﬁ  batide or abxicimab to achieve a 
target ACT value of 275–325 seconds. Four patients (2.6%) 
suffered the primary endpoint of death, myocardial infarction 
or need for revascularization within 30 days. Major bleeding 
was observed in 2 (1.3%) of patients. The authors suggested 
that during elective PCI argatroban in conjunction with 
a GP IIb/IIIa antagonists provides adequate anticoagulation 
with minor bleeding complications (Jang et al 1999).
In the MINT (Myocardial Infarction with Novastan 
and rTPA) study, the effect of argatroban and ﬁ  brinolytic 
therapy was compared to heparin plus ﬁ  brinolytic therapy 
in 125 patients with acute myocardial infarction (AMI) 
(La Monte et al 2004). Argatroban was given in a low 
dose with a 100 μg/kg bolus and infusion of 1 μg/kg/min 
(n = 38) or a high dose with the same bolus but an infusion 
of 3 μg/kg/min(n = 47) with recombinant tissue factor plas-
minogen activator (rTPA). These patients were compared 
with 40 patients with heparin and rTPA anticoagulation. The 
composite endpoint of death, recurrent myocardial infarction, 
cardiogenic shock or congestive heart failure, revasculariza-
tion, and recurrent ischemia within 30 days occurred in 37.5% 
of heparin patients, 32% of low-dose argatroban patients, and 
25.5% of high dose argatroban patients. Major bleeding was 
observed in 10% of heparin patients, 2.6% of low dose arg-
atroban patients, and 4.3% of high dose argatroban patients 
(La Monte et al 2004). The authors concluded that argatroban 
together with rTPA appears to provide improved reperfusion 
after AMI when compared to heparin and rTPA.
Argatroban anticoagulation in acute 
ischemic stroke
There are only a few small clinical pilot studies in which 
argatroban anticoagulation has been investigated outside 
the setting of HIT(TS). The ARGIS-1 study is a random-
ized, double blinded, placebo controlled study of the use 
of argatroban in acute ischemic stroke (Sugg et al 2006). In 
this investigation, 112 patients with acute ischemic stroke 
(<12 hours from onset) received argatroban at two different 
dosages (bolus 100 μg/kg followed by a continuous infusion 
of 3 μg/kg/min, n = 59 or 1 μg/kg/min, n = 58) to achieve 
target aPTT values of 2.25 and 1.75 of baseline value. The 
control group consisted of 54 patients. The primary endpoint 
was symptomatic intracranial hemorrhage (ICH) within 30 
days. The mean infusion doses were 2.7 and 1.2 μg/kg/min 
for the high- and the low-dose groups, respectively. Target 
aPTT values were achieved within 2 hours after initiation of 
therapy. No major symptomatic hemorrhage was observed 
during the period of investigation and minor systemic hem-
orrhage increased only with high dose argatroban versus 
placebo (27.1% vs 11.1%). The 90-day mortality was 13.5% 
with no difference in survival rates between groups.
Preliminary results of 15 patients with acute stroke 
enrolled into the argatroban-rTPA study are available (Arpino 
and Hallisey 2004). In this investigation the dosing of the Biologics: Targets & Therapy 2007:1(2) 110
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lower-dose group of the ARGIS-1 study was combined 
with rTPA lysis. Primary outcome was incidence of ICH 
and secondary outcome complete re-canalization after 2 
hours. Symptomatic ICH occurred in 2 patients and asymp-
tomatic bleeding in 1 patient and there was 1 death. Com-
plete re-canalization was achieved in 6 patients and partial 
re-canalization in 4 patients; re-occlusion occurred in 
3 patients. The authors concluded that the safety proﬁ  le of 
this protocol may be within acceptable limits and that its 
efﬁ  cacy for achieving fast and complete re-canalization is 
promising, but that further data are needed.
Argatroban for anticoagulation 
during renal replacement therapy
The half-life of argatroban is moderately extended in 
patients with renal insufﬁ  ciency: At a creatinine clear-
ance of 0–29 mL/min, the half-life of argatroban was 
64 ± 35 min versus 47 ± 22 min at a creatinine clearance 
80 mL/min (p = 0.58) (Swan and Hursting 2000). Even 
though a correlation of creatinine clearance and aPTT-
adjusted argatroban dose has been described (Arpino and 
Hallisey 2004; Guzzi et al 2006), a recent retrospective 
analysis of multicenter trial data suggests this correlation 
not to be of clinical signiﬁ  cance, and initial adaptation 
of the argatroban dose to renal function was regarded as 
unnecessary (Guzzi et al 2006).
Concerning intermittent hemodialysis (HD), a prospec-
tive crossover study of 13 maintenance HD patients showed 3 
different argatroban dosing regimens (250 μg/kg bolus alone, 
with an additional 250 μg/kg bolus allowed; 250 μg/kg bolus 
followed by 2 μg/kg/min infusion, or 2 μg/kg/min infusion 
at steady state with initiation of argatroban infusion 4 hours 
before dialysis) to be safe and well tolerated (Murray et al 
2004). In a retrospective analysis of 47 patients with HIT and 
renal failure requiring renal replacement therapy, argatroban 
provided effective anticoagulation with an acceptable safety 
proﬁ  le (Reddy et al 2005).
In ICU patients suffering from renal, but not measurable 
liver insufﬁ  ciency, however, dose reductions may be fre-
quently necessary (unpublished observations of the author). 
Based on this experience, in ICU patients we start argatroban 
at a reduced dose, provided there is no acute thrombosis. 
Careful monitoring and dosing are speciﬁ  cally required in 
this patient population. Similar experiences have also been 
reported by others (de Denus and Spinler 2003; Guzzi et al 
2006). Here, decreased cardiac output or hepatic congestion 
has been discussed as causing reduced argatroban require-
ments (Guzzi et al 2006).
Whether anticoagulation with argatroban alone always 
prevents clotting in the extracorporeal circuit is unclear. 
In one HIT patient on HD treated with argatroban, marked 
spontaneous platelet aggregation occurred, perhaps due to 
HIT together with the additional platelet activation known 
to occur in HD (Koide et al 1995). In this case, aspirin was 
added to achieve patency of the extracorporeal circuit.
Dialytic argatroban clearance by high-ﬂ  ux hemodialyzer 
membranes is regarded as being clinically insigniﬁ  cant 
(Murray et al 2004; Tang et al 2005). However, as both 
low-ﬂ  ux and high-ﬂ  ux membranes show signiﬁ  cant argatro-
ban sieving (Krieger et al 2007), hemoﬁ  ltration appears to be 
a suitable rescue measure if rapid removal of argatroban is 
required, eg, in the case of bleeding or accidental overdose, 
especially if hepatic clearance is reduced.
Its predominant hepatic elimination makes argatroban favor-
able for alternative anticoagulation in chronic renal failure. Its 
role and dosing in ICU patients suffering from acute renal failure 
requiring renal replacement therapy remain to be deﬁ  ned.
Conclusion
Heparin-induced thrombocytopenia is a not infrequent, 
severe disease associated with potentially catastrophic 
thromboembolic complications. The data of the ARG-911 
and ARG-915 investigations provide convincing evidence 
that argatroban enables rapid and effective anticoagulation in 
this condition and is an effective therapy for HIT-associated 
complications. Furthermore, in comparison with the direct 
competitor lepirudin, a DTI which is eliminated exclusively 
via the renal system, the safety margin of argatroban appears 
to be extended, as shown by the lower rate of major bleeding 
events than in the lepirudin studies.
Renal impairment with the need for renal replacement 
therapy is a frequent complication of HIT, especially in ICU 
patients. Particularly in this indication argatroban anticoagu-
lation appears to be a very promising option. However, more 
investigations in this ﬁ  eld are needed and reliable protocols 
for dosing should be established.
In the ﬁ  eld of PCI in HIT patients data are less convincing 
and the optimal dose to prevent the frequent need of re-bolusing, 
for example, has not yet been established. Data obtained in 
this special indication with bivalirudin, another short-acting 
DTI that is emerging as a replacement for heparin in PCI, 
suggest a more constant dose–effect relation associated with 
a convincing efﬁ  cacy and safety proﬁ  le (Lincoff et al 2003; 
Mahaffey et al 2003; Stone et al 2006).
In the ﬁ  elds outside HIT, results obtained in patients 
with acute stroke are interesting and deserve further detailed Biologics: Targets & Therapy 2007:1(2) 111
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investigation. However, before data from larger studies are 
available all studies outside HIT have the character of pilot 
investigations. Moreover, special patient populations, par-
ticularly patients on the ICU, need further attention in order 
to establish reliable dosing schemes and protocols.
The practical problem of transition from argatroban 
anticoagulation to oral anticoagulants requires a standard pro-
tocol for the condition of HIT(TS) and in non-HIT patients. 
Use of more speciﬁ  c assays to monitor argatroban, such as 
the ECT, may be helpful in this regard.
We conclude that argatroban is a valuable drug for the 
condition of HIT(TS) that needs more detailed investigation in 
a large number of special indications and clinical settings.
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